Lymphoproliferative Disorders
- Author: Stuart S Winter, MD; Chief Editor: Robert J Arceci, MD, PhD more...
Background
Lymphoproliferative disorders (LPDs) in children represent a heterogeneous group of expanding, monoclonal or oligoclonal, lymphoid cells that occur in the setting of immune dysfunction. The risk of true malignancy in affected children is significantly higher than the risk in immunocompetent children. Treatment must be tailored to the child's underlying immune disorder, to the aggressiveness of the clone, and to the likelihood of causing clinically significant toxicity.
In this article, underlying immunodeficiency disorders are reviewed in the context of the type of lymphoproliferative disorder encountered.
Pathophysiology
See Causes.
Epidemiology
Frequency
United States
Lymphoproliferative disorders occur in children with immunodysfunction. Because this is a heterogeneous disease group, the incidence rate is difficult to estimate.
Mortality/Morbidity
Mortality and morbidity in children vary considerably and depend on the underlying immunodeficiency syndrome.
Race
Overall, no significant racial predilection has been reported.
Sex
The overall male-to-female ratio is 1:1, except for X-linked immunodeficiency syndromes, which primarily affect male individuals; however, X-linked immunodeficiency syndrome occasionally affects female individuals. In scenarios such as this, mutations in the gene that encodes NFkappaB essential modifier (NEMO), which can be inherited in autosomal dominant fashion, lead to immunodeficiency syndromes in members of both sexes.
Age
Lymphoproliferative disorders can occur in any age group but are relatively uncommon in infants and toddlers. They become progressively more common with age.
Spector BD, Perry GS III, Kersey JH. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency--cancer registry. Clin Immunol Immunopathol. Sep 1978;11(1):12-29. [Medline].
Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol. Oct 2003;3(10):813-21. [Medline].
Latour S. Natural killer T cells and X-linked lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol. Dec 2007;7(6):510-4. [Medline].
Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol. Apr 2006;133(2):124-40. [Medline].
Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol. Jan 2008;15(1):22-9. [Medline].
Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol. Jan 2008;15(1):30-6. [Medline].
Ohta H, Fukushima N, Ozono K. Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation. Int J Hematol. Sep 2009;90(2):127-36. [Medline].
Baehner RL. Lymphocytes. In: Miller DR, Baehner RL, eds. Blood Diseases in Infancy and Childhood. St. Louis, MO: CV Mosby; 1990:578-603.
Bird AG, Britton S. The relationship between Epstein-Barr virus and lymphoma. Semin Hematol. Oct 1982;19(4):285-300. [Medline].
Brusamolino E, Pagnucco G, Bernasconi C. Secondary lymphomas: a review on lymphoproliferative diseases arising in immunocompromised hosts: prevalence, clinical features and pathogenetic mechanisms. Haematologica. Nov-Dec 1989;74(6):605-22. [Medline].
Certain S, Barrat F, Pastural E, et al. Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome. Blood. Feb 1 2000;95(3):979-83. [Medline].
Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol. Mar 1993;99(3):265-76. [Medline].
Fiorilli M, Carbonari M, Crescenzi M, et al. T-cell receptor genes and ataxia telangiectasia. Nature. Jan 17-23 1985;313(5999):186. [Medline].
Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. Feb 2006;33 Suppl 1:58-70. [Medline].
Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol. Dec 1989;135(6):977-87. [Medline].
Loughrey M, Trivett M, Lade S, et al. Diagnostic application of Epstein-Barr virus-encoded RNA in situ hybridisation. Pathology. Aug 2004;36(4):301-8. [Medline].
Lundell R, Elenitoba-Johnson KS, Lim MS. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol. Jul 2004;28(7):967-73. [Medline].
Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. Aug 2005;130(3):325-32. [Medline].
Nichols KE. X-linked lymphoproliferative disease: genetics and biochemistry. Rev Immunogenet. 2000;2(2):256-66. [Medline].
Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. Nov 2 2006;444(7115):110-4. [Medline].
Sanal O, Wei S, Foroud T, et al. Further mapping of an ataxia-telangiectasia locus to the chromosome 11q23 region. Am J Hum Genet. Nov 1990;47(5):860-6. [Medline].
Sander CA, Medeiros LJ, Weiss LM, et al. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am J Surg Pathol. Dec 1992;16(12):1170-82. [Medline].
Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. Jun 2004;28(6):794-800. [Medline].
Straus SE, Sneller M, Lenardo MJ, et al. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. Apr 6 1999;130(7):591-601. [Medline].
Su HC, Lenardo MJ. Genetic defects of apoptosis and primary immunodeficiency. Immunol Allergy Clin North Am. May 2008;28(2):329-51, ix. [Medline].
Uzel G. The range of defects associated with nuclear factor kappaB essential modulator. Curr Opin Allergy Clin Immunol. Dec 2005;5(6):513-8. [Medline].
Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. Jan 21 1993;361(6409):226-33. [Medline].

